 |
|
|
| |
Impact of Bulevirtide Treatment on Patient-Reported
Outcomes Among Patients With Hepatitis Delta in Europe
|
| |
| |
EASL 2026 May 26-30 Barcelona
Maria Buti1,2, Fritha Hennessy3, Tia Pennant3, Daniel Graham3, Fraser Barrable3, Alastair Hinds3, Caroline Burk4, Chong Kim4, Marvin Rock4, Pietro Lampertico5,6
1Liver Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain; 2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) del Instituto Carlos III, Madrid, Spain; 3Adelphi Real World, Bollington, UK; 4HEOR-Global Value & Access, Gilead Sciences, Inc., Foster City, CA, USA; 5Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; 6CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
|
| |
|
|
|
|
|
